Legend

Big Data for Better Health

Keeping the Person in Personalised Health

Personalised Health and Human Disease

Cancer: A paradigm for Personalised Health

Personalised Health and Policy Agenda

Driving The Innovation Agenda

EUROPEAN UNION (EU) PRESIDENCY EVENT
European Alliance for Personalised Medicine Congress: Personalising Your Health: A Global Imperative!
10:0 – 10:30Press Conference
10.30 – 11.15Opening of EAPM Congress
Co-Chair: Denis Horgan, Executive Director, European Alliance for Personalised Medicine (EAPM) Brussels, Belgium
Welcome: David Byrne, Former European Commissioner for Health and Consumer Protection and Co-Chair EAPM, Brussels, Belgium
Mark Lawler, Chair in Translational Cancer Genomics, Queen’s University Belfast, UK
Minister of Health, Northern Ireland (TBC)
Simon Harris, Minister of Health, Republic of Ireland (TBC)
Kersti Kaljulaid, President of Estonia (TBC)
11.15 – 13:00Opening Plenary Presidential Session: Round Table “Growth in Personalised Healthcare – The promise for future generations”
Co- Chair: Gordon McVie, Co-Chair EAPM, Brussels, Belgium
Patrick Johnston, Vice Chancellor, Queen’s University Belfast, UK
Mary Baker, Former President European Brain Council,Brussels, Belgium
Mark Caulfield, Chief Scientist, Genomics England, Cambridge, UK
Andina – Ioana Valean, ENVI Committee Chair, European Parliament, Brussels, Belgium (TBC)
Patrick Vallance, President R&D, GlaxoSmithKline, US (TBC)
13.00 – 13:45Lunch and Networking
13.45– 15.30Parallel Sessions
Centre for Cancer Research and Cell Biology 10 Year Anniversary SymposiumThe Value of Sustainable HealthcareEuropean Hematology Association Session – Personalising treatment of blood diseases –  Taking advantage of the leukemia/lymphoma genomeCapturing the Global Picture in Precision MedicineA Tale of Two Cities: a whole system approach to personalised medicine and health
Chair: David Waugh, Director, Centre for Cancer Research and Cell Biology, Belfast, UKChair: Denis Horgan, Executive Director, European Alliance for Personalised MedicineChair: Ulrich Jäger, Professor of Hematology, Medical University of Vienna, AustriaCo-Chair: Richard Barker, Center for the Advancement of Sustainable Medical Innovation (CASMI), Oxford/University College London, UKChair: Gianni D’Errico, European Funding Officer, Regional Foundation for the Biomedical Research, Lombardy, Milan, Italy
Co-Chair Mark Lawler Centre for Cancer Research and Cell Biology, Queen’s University Belfast, UKCo-Chair Michael Paul Messenger, Principal Healthcare Scientist, Leeds Institute of Cancer & Pathology, Leeds, UK
Speakers to be confirmedKaisa Immonen, Director of Policy, European Patient Forum, Brussels, BelgiumPersonalisation in hematology – Ulrich Jäger, Professor of Hematology, Medical University of Vienna, AustriaSpeaker to be confirmed, Datar Genetics Limited, New Delhi, India“PPM+The Leeds Care Record: Big Data supporting PM” Dr Geoff Hall, Chief Clinical Information Officer, Leeds Teaching Hospital NHS Trust, Leeds, UK (TBC)
Maarten IJzerman, Chair Department of Health Technology & Services Research,   University of Twente, NetherlandsThe hematology research roadmap Christine Chomienne, Institut National du Cancer, Paris FranceSpeakers to be confirmedEarly Health Economic Modelling – developing the evidence of value – Dr Bethany Shinkins, Test Evaluation Group Lead, University of Leeds, Leeds, UK (TBC)
The HARMONY project (speaker to be confirmed)“Overview of the management of people affected by chronic disease” Paolo Mocarelli, Scientific Director of “don Gnocchi Foundation”, Milan, Italy (TBC)
Magda Chlebus, Director Science Policy, EFPIA. Brussels, Belgium (TBC)“Prevention of Chronic diseases and benefits for the healthcare systems” Prof. Sergio Abrignani  Scientific Director Istituto Nazionale di Genetica Molecolare, Milano, Italy
Access to Innovative Medicines – Anton Hagenbeek, University of Amsterdam-Academic Medical Centre, The Netherlands“Public Consultation on PM in Lombardy Regions – Overviews and scientific, industrial and policy outcomes” Luca del Gobbo, Regional Ministry University, Research and Open Innovation, Milan, Italy
“Accelerating PM and Health – a whole system approach” Michael Paul Messenger, Principal Healthcare Scientist, Leeds Institute of Cancer & Pathology, Leeds, UK
15.30 – 17.00Presidential Session – Shaping Future Healthcare and the One Health Agenda I
Sue Hill, OBE, Chief Scientific Officer, NHS England, UK
Sir John Bell Regius Professor of Medicine, Oxford University, and Chairman of the Office for the Strategic Coordination of Health Research, UK (TBC)
Ian Young, Chief Scientific Advisor, Department of Health, Social Services and Public Safety, Belfast, Northern Ireland
Denis Lacombe, Director General, European Organisation for Research and Treatment of Cancer, Brussels, Belgium
17.00 – 17:15Coffee, Posters and Networking
17.15 – 19.00Presidential Session – Shaping Future Healthcare and the One Health Agenda II
Co-Chair: Virginia Acha, Executive Director, Research, Medical and Innovation, Association of the British Pharmaceutical Industry (ABPI), UK
Co-Chair (TBC)
Peter Hongaard Anderson, Innovation Fund , Denmark
Atul Gawande, Professor of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, USA
Richard Barker, OBE, Center for the Advancement of Sustainable Medical Innovation (CASMI), University of Oxford/University College London, UK
Koen Kas, Professor of Biochemistry, University of Gent, Belgium
19.00- 20.00Special lecture
Alexander Eggermont, Director General, Institute Gustave Roussy, Paris, France
20:30 – 22:00Welcome Reception, Belfast City Hall (hosted by Lord Mayor)
Mike Thompson, Chief Executive Officer, Association of British Pharmaceutical Industries, UK
Kersti Kaljulaid, President, Estonia (TBC)
07:30 – 08:15Highlights of the Day and Press Briefing
07:30 – 08:30Meet the Policy Maker:Meet the ProfessorMeet the Professor/Business LeaderMeet the Patent AdvocateMeet the Professor/Business Leader
08:30 – 10:00Presidential Session: Big Data Saves Lives
Co-Chair: Mark Lawler, Chair in Translational Cancer Genomics, Queen’s University Belfast, UK and Co-Chair Clinical Cancer Genomic Task Team, Global Alliance for Genomics and Health (GA4GH);
Co-Chair: Julie Wilson, Associate Director, Welcome Trust Sanger Centre Cambridge UK and Global Alliance for Genomics and Health (GA4GH)
Ewan Birney, Director European Bioinformatics Institute, Cambrdge UK and Chair Global Aliance for Genomics and Health
Andrew Morris, Director, Health Data Research UK
Mene Pangalos, Executive Vice President Innovative Medicines and Early Development Biotech Unit, AstraZeneca Cambridge, UK (TBC)
Margaret Grayson Chair Northern Ireland Cancer Research Consumer Forum, Belfast, UK
Ain Aaviksoo, Deputy Secretary General for E-services and Innovation, Ministry of Social Affairs, Estonia
Ernst Hafen, Institute of Molecular Systems Biology, ETH Zurich, Switzerland
10:00 – 10:30Coffee, Posters and Networking
Speed Networking
10:00 – 10:30Meet the Cancer PatientMeet the Diabetes PatientMeet the Patient (Brain Diseases)Meet the Patient with co-morbiditiesMeet the Rare Disease Patient
10:30 – 12:15Parallel Sessions
 National Cancer Institute – CCRCB Special SymposiumUlster University Session on Precision Medicine in Multi-morbid Inflammatory DiseaseCentre for Experimental Medicine (CEM) Queen’s University Belfast Special Session: Eyes do not lie – you are what you can see! Options for personalised medicine in eye diseasesEuropean Bioinformatics Institute-Global Alliance for Genomics and Health (GA4GH) Special Session Empowering personalised health through data sharingConverting Hospitals to a Personalised Health Agenda
Chair: Nick Orr, Team Leader, Institute of Cancer Research, London, UKChair: (TBC)Chair: Tunde Peto, Centre for Experimental Medicine, Queen’s University Belfast, UKChair: Serena Scollen, Head of Human Genomics and Translational Data, Elixir, Cambridge, UKChair: Pascal Garel, Chief Executive, Hospital and Healthcare Federation (HOPE), Brussels, Belgium
Marie Therese Landi, Principal Investigator, Division of Cancer Epidemiology & Genetics, Integrative Tumor Epidemiology , National Cancer Institute Washington, USA (TBC)“Stratified Medicine in Proinflamatory Disease”
Tony Bjourson
Northern Ireland Centre for Stratified Medicine
“Pharmacogenetics and the individual patient: the industry perspective” Everson Nogoceke, Biomarker Experimental Medicine Leader, Roche Pharma Research & Early Development, Roche, Basel, SwitzerlandJulie Wilson, Associate Director, Welcome Trust Sanger Centre, Cambridge, UK; Clinical Working Group, Global Alliance for Genomics and Health (GA4GH)Regional Level – Eva Weinreich-Jensen, Vice-President, HOPE & Senior Adviser, Danish Regions, Denmark
Jean Claude Zenklusen, Director, The Cancer Genome Atlas, National Cancer Institute, Washington, USA (TBC)Speakers to be confirmed“Precision Ophthalmology: Lessons from age related macular disease” Carel Hoyng, Professor of Ophthalmology, Radboud University Nijmegen Medical Centre, Nijmegen, The NetherlandsSerena Scollen, Head of Human Genomics and Translational Data, Elixir, Cambridge, UK“National Level” Michael McBride, Chief Medical Officer,Department of Health Northern Ireland, Belfast, UK (TBC)
Aimee Kramer, Division of Cancer Epidemiology & Genetics, Infections and Immunoepidemiology Branch, National Cancer Institute, Washington, USA (TBC)“The myopia epidemic: can we individualise the message?” Caroline Klaver, Professor of Ophthalmology at Erasmus MC & Radboud UMC The NetherlandsThomas Keane, Team Leader: EGA, EVA and archive infrastructure EMBL-EBIOther Speakers to be Confirmed
Micronutrients and age related eye disease: from diet through drugs to prevention of blindness” Imre Lengyel, Centre for Experimental Medicine, Queen’s University Belfast, UKTorsten Schwede, Professor of Bioinformatics, Swiss Institute of Bioinformatics, University of Basel, Switzerland
“Curing diabetic eye disease? – from the bench to treating patients as individuals” Alan Stitt, Professor, Centre for Experimental Medicine, Queen’s University Belfast, UKSarion Bowers, Policy Lead Sanger Institute
“How to improve imaging technology to accommodate individual needs?” Anne-Marie Cairns, Global Vice President of Clinical & Medical Affairs, Optos, Halbeath, UKJeff Barrett, Director, Centre for Therapeutic Target Validation,   Cambridge, UK
12:00 – 12.30Proffered Paper PresentationsProffered Paper PresentationsProffered Paper PresentationsProffered Paper PresentationsProffered Paper Presentations
12:30 – 13:30Lunch, Posters and Networking
13:00 – 14:30Presidential Session: Research Frontiers in Personalised Medicine
Co-Chair: Mairead O’Driscoll, Health Research Board of Ireland, Dublin,Ireland and IC-Per Med
Co-Chair (TBC)
Holger Hess-Stumpp, Director, Global External Innovation & Alliance, Oncology, Bayer Healthcare, Leverkusen, Germany (TBC)
Speaker to be confirmed
William Pao, Global Head, Oncology Discovery & Translational Area (pRED), Roche, Basel, Switzerland (TBC)
Alberto Bardelli, President, European Association for Cancer Research, Torino, Italy
14:30 – 15:00Coffee, Posters and Networking
Speed Networking
14:30 – 15:00Meet the Cancer PatientMeet the Diabetes PatientMeet the Patient (Brain Diseases)Meet the Patient with co-morbiditiesMeet the Rare Disease Patient
15:00 – 16:30Parallel Sessions
Mini Symposium: Breast Cancer: Dealing with Complexity Head on to Better Personalised TreatmentGenomics and Medicine – Crossing the RubiconRealising precious therapeutics in neurological diseaseCCRCB – ALMAC Session – The Realities of Delivering Personalised Medicine in Clinical TrialsSpecial Symposium: Implementing existing knowledge and innovation – a European Perspective
Chair: Liam Gallagher, Director Conway Institute for Biomolecular Research, University College Dublin, IrelandChair: Shane McKee, Director Northern Ireland Genomics Medicine Centre, Belfast, UKChair: Gianpiero Cavalleri, Associate Professor in Human Genetics Royal College of Surgeons in Ireland, Dublin, IrelandChair: Richard Kennedy, McClay Professor in Medical Oncology Queen’s University Belfast, UKChair: Peter Selby, President, European Cancer Concord (ECC)
Professor Martine Piccart, Professor of Oncology, Université Libre de Bruxelles; Director of Medicine, Jules Bordet Institute, BelgiumSir John Burn, Professor of Clinical Genetics University of Newcastle, UKKen Emancipator, Executive Medical Director,   Merck, New York, USAFrancoise Meunier, Vice-President, Federation of European Academies of Medicine, Brussels, Belgium
Alric Rüther, MD, PhD Head, Department of Health Care Quality, International Affairs, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany (TBC)Sally John, VP Genomics and Computational Biology, Biogen, Cambridge, USA (TBC)Slave Petrovski, NHMRC Fellow, Royal Melbourne Hospital, University of Melbourne, AustraliaDarren Hodgson, Senior Principal Translational Scientist, AstraZeneca, Stcckport, UKArnie Purushotham, Director of King’s Health Partners Cancer Centre (KHPCC), Chair of Breast Cancer at King’s College London (KCL) Trust (TBC)
Professor Fergus Couch, Professor and Chair, Division of Experimental Pathology, Mayo Clinic, USANadeem Sarwar, President, Eisai AiM Institute, Boston USA (TBC)eHealth talk: Mary Fitzsimons, Medical Physicist, Beaumont Hospital, Dublin, IrelandMatt Squires, Executive Director Oncology Precision Medicine Novartis, Basel,SwitzerlandPeter Selby, President, European Cancer Concord (ECC)
“Involving the public in conversations about Genomics: making Personalised Medicine resonate” Anna Middleton Head of Society and Ethics Research Wellcome Genome Campus, Cambridge, UK“Clinical integration” Norman Delanty, Professor of Clinical Neurological Sciences, Beaumont Hospital, Dublin, IrelandSpeaker to be confirmed
16:30 – 17:30Proffered Paper PresentationsProffered Paper PresentationsProffered Paper PresentationsProffered Paper PresentationsProffered Paper Presentations
17:00 – 17:30Coffee, Posters and Networking
17:30 – 19:00Harmony SessionClinical Innovation Showcase: ‘Northern Ireland Clinical Research Network(NICRN) : supporting clinical research in personalised medicine’Imaging and Personalised Medicine
Chair: Carin Smand, Managing Director, EHA (TBC)Co-Chairs: Paul Biagioni, Maurice O’ Kane NICRNChair: Bernd Hamm, President, European Society of Radiology
“Introduction” Maurice O’Kane NICRN
Other speakers to be confirmed
19:00 – 20:00CCRCB Lecture
19:00 – 20:00Poster Session
20:30 – 22:30Gala Dinner Titanic Belfast
Taavi Rõivas, former leader of the Reform Party and former Prime Minister of Estonia (TBC)
07:30 – 08:00Highlights of the Day and Press Briefing
07:30 – 08:30Meet the Policy MakersMeet the Professor/Business LeaderMeet the Professor/Business LeaderMeet the Policy MakersMeet the Professor/Business Leader
08:00 – 09:30Presidential Session: Is precision medicine the route to a healthy world?
Chair: John Bowis, Former Minister for Health UK and Former MEP
Taavi Rõivas, former leader of the Reform Party and former Prime Minister of Estonia (TBC)
Harold Varmus, New York Genome Centre, USA (TBC)
Carlos Moedas, Commissioner, DG Research, Science and Innovation, Brussels, Belgium (TBC)
Ruth McKernan CBE, Chief Executive, Innovate UK (TBC)
Ian Banks, President, European Men’s Health Forum
Tom Lillie, Vice President, Head of European Clinicial Development MSD, London, UK
09:30 – 10:00Coffee, Posters and Networking
10:00 – 11:30Parallel Sessions
Personal Oncology Approaches – reflections from both sides of the pondThe ‘molecularly unstratified’ patient: a focus for moral, psycho-social and societal researchGenomics and ReimbursementImmunotherapy: The next Big Thing?Preserving Health – what can we do at European Level?
Chair: Etienne Richter, Associate Director, CIHR Institute of Genetics, Montreal, CanadaChair: Deborah Alsina, Chief Executive MBE, Bowel Cancer UKChair: Jonathan Truelove, Vice President, General Counsel – International, Genomic Health, Geneva, SwitzerlandChair: Gennaro Ciliberto, Scientific Director, IRCCS, Instituto Nazionale Tumori “Regina Elena, Rome, ItalyChair: Tit Albreht, Institute of Public Health, Slovenia;
Fabien Calvo, Scientific Director, Cancer Core Europe, Paris, FranceTim Maughan, Professor of Clinical Oncology, University of Oxford; MRC/CRUK Stratification in Colorectal Cancer ConsortiumSheila Walcoff, Founder and CEO, Goldbug Strategies, Washington, USA“Immunophenotypes and antigenomes of solid cancers” Zlatko Trajanoski, Director, Division for Bioinformatics,  Biocenter, Innsbruck Medical University (TBC)Sebastian Schmidt, Head of Strategy and Medical Affairs Computed Tomography at Siemens Healthineers
“Biomarkers for Pediatric Glioblastoma through Genomics and Epigenomics” Nada Jabado, Associate Professor of Pediatrics, McGill University Health Centre, Montreal, CanadaJoshua Hordern, Associate Professor of Christian Ethics, University of Oxford; Oxford Healthcare Values Partnership, University of OxfordStephen Lee, Biosciences Team Manager, Medicines and Healthcare products Regulatory Agency, London, UK (TBC)“Clonal neoantigens and sensitivity to immune checkpoint blockade” Sergio Quezada, Professional Research Fellow, Research Department of Hematology, UCL Cancer Institute (TBC)“Public health genomics” Dr Marc Van den Bulcke, Head Cancer Centre, OD Public Health and Surveillance   Scientific Institute of Public Health, Belgium
“Personalized Cancer Immunotherapy” – Denis Claude Roy, Director Cellular Therap Laboratory, Scientific Director, Centre de recherche, Hospital Maisonneuve-Rosemont, Montreal, CanadaRichard Sullivan, Chair in Cancer Policy and Global Health, Kings College LondonSue Spencer, Head of Global Medical Device Services, UL, UK (TBC)“Development of neoantigen-based cancer”Ugur Sahin, co-founder and CEO of BioNTech AG, Mainz, Germany (TBC)“Cancer screening” Dr Ahti Anttila, Research Director of the Mass Screening Registry of the Finnish Cancer Registry (TBC)
“Personalized Oncogenomics (POG), The BC Cancer Agency’s Personalized Oncogenomics Program” Marco Marra, Director and Distinguished Scientist, Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, CanadaAlison Hall, Head of Humanities, PHG Foundation, Cambridge, UKDr Panos Kanavos, Reader in International Health Policy Department of Social Policy, London School of Economics, London, UK“Design and testing of novel concepts for adoptive immunotherapy of cancer” Ton Schumacher, Group Leader, Immunology, Netherlands Cancer Institute (TBC)Michel Coleman, Professor of Epidemiology and Vital Statistics, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK (TBC)
Liz Morrell, Postdoctoral researcher, Centre for the Advancement of Sustainable Medical Innovation (CASMI), Radcliffe Department of Medicine, University of Oxford, UKBritish Standards Institution representative (speaker to be confirmed)Jim Cassidy, Corporate Vice President, Translational Development, Celgene , (TBC)“Survivorship issues” Dr Claudia Ferrari, Department of Training and Demography for Health Professionals, The French National Cancer Institute (TBC)
Rob Horne, Professor of Behavioural Medicine, UCL School of Pharmacy;  Centre for the Advancement of Sustainable Medical Innovation, London, UKStephan Scherer, VP Global Head Correlative Science, Novartis (TBC)
Alastair Kent, Chair Rare Disease UK; Director, Genetic Alliance UK
11:30 – 12:00Proffered Paper PresentationsProffered Paper PresentationsProffered Paper PresentationsProffered Paper PresentationsProffered Paper Presentations
12:00 – 13:00Lunch, Posters and Networking
13:30 – 15.00Presidential Session: Female Leaders and Innovators Forum; An Athena Swan Initiative
Chair: Mary Harney, Former Minister for Health and Deputy Prime Minister, Ireland
Francoise Meunier, Director of Special Projects, European Association for the Research and Treatment of Cancer, Brussels, Belgium, Vice-President, Federation of European Academies of Medicine, Brussels, Belgium
Johanna Joyce, Ludwig Institute for Cancer Research, University of Lausanne, Switzerland (TBC)
Speaker to be Confirmed
14:30 – 15:00Coffee, Posters and Networking
 Patient Advocacy Award
15:00 – 16:30Parallel Sessions
 Princess Margaret Cancer Centre – CCRCB Special SymposiumPersonalised Medicine and Public Health: Two Sides of the Same Coin?Fixing Cystic Fibrosis Transmembrane Conductance Regulator (CFTR): Targeting therapies which make a difference Genomics, DNA and Diaspora
Chair: Lillian Siu, Professor of Medicine, Princess margaret Cancer Centre, University of Toronto, CanadaChair: Walter Ricciardi, Instituto Superiore di Sanità ItalyCo-Chair: J Stuart Elborn, Imperial College and Royal Brompton Hospital, London and Queen’s University Belfast, UKCo-Chair: Eimear Kenny, Assistant Professor, Icahn School of Medicine at Mount Sinai, NY, USA
Co-Chair: Lorraine Martin, Professor of Molecular Pharmaceutics, School of Pharmacy, Queen’s University Belfast, UKCo-Chair Joe McHugh T.D., Minister of State for the Diaspora and International Development (TBC)
“How the Cystic Fibrosis Transmembrane Regulator (CFTR) works” Lorraine Martin, Professor of Molecular Pharmaceutics, School of Pharmacy, Queen’s University Belfast, UK
“Risk Stratification Approaches in the Management of Locoregionally Advanced Head and Neck Squamous Cell Cancer Jean” Pascal Machiels, MD, PhD, Université catholique de Louvain, Brussels, BelgiumSpeaker to be confirmed“Modulating the Cystic Fibrosis Transmembrane Regulator (CFTR): How New Drugs were developed” Mark Higgins, Vertex, Boston, USJohn Greally, Professor, Faculty Scholar for Epigenetics, Albert Einstein College of Medicine, New York, USA
“The Changing Epidemiological and Molecular Landscape of Head and Neck Squamous Cell Cancer: A Global Perspective” Hisham Mehanna, MBChB, PhD, University of Birmingham, Birmingham, UKFrank Kee, Director, UKCRC Centre for Excellence for Public Health Research (NI), Queen’s University Belfast, UK“Treating Cystic Fibrosis: New Clinical Trials.” J Stuart Elborn, Imperial College and Royal Brompton Hospital, London and Queen’s University Belfast, UKDan Bradley, Principal Investigator, molecular Population Genetics, Smurfit Institute of Genetics, Trinity College Dublin
“Oncolytic Viruses and Immune Checkpoint Inhibitors in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer” Kevin Harrington, MBBS, PhD, The Institute of Cancer Research, London, UKKaisa Immonen, Director of Policy, European Patient Forum“Living with Cystic Fibrosis” Michelle Francis Naylor, Belfast, UKEimear Kenny, Assistant Professor, Icahn School of Medicine at Mount Sinai, NY. USA
Xavier Prats Monne, Director-General for Health and Food Security – DG SANTE, European Commission, Brussels, Belgium (TBC)“Future Challenges, Policy and Science” Janet Allen, Director of Strategic Innovation, Cystic Fibrosis Trust, Southampton, UKTõnu Esko Deputy Director of Research, Estonian Biobank, Estonian Genome Center, University of Tartu, Estonia (TBC)
16:30 – 17:00Proffered Paper PresentationsProffered Paper PresentationsProffered Paper PresentationsProffered Paper PresentationsProffered Paper Presentations
17:00 – 17:30Coffee, Posters and Networking
 Speed Networking
Meet the Cancer PatientMeet the Diabetes PatientMeet the Patient (Brain Diseases)Meet the Patient with co-morbiditiesMeet the Rare Disease Patient
17:30 – 19:00Shooting for the Moon or Flying too near the Sun: Crossing the Value Rubicon in Precision Care
Co-Chair: Mark Lawler Chair in Translational Cancer Genomics, Queen’s University Belfast, UK
Co-Chair Richard Sullivan, Director, Institute of Cancer Policy, King’s College London UK
Richard Sullivan, Director, Institute of Cancer Policy, King’s College London
Tito Fojo, Professor of Medicine, Columbia University, New York, USA
Mark Lawler, Chair in Translational Cancer Genomics, Queen’s University Belfast, UK
William MacKillop, Division of Cancer Care and Epidemiology Queen’s University Cancer Research Institute Kingston, Ontario, Canada (TBC)
Virginia Acha, Executive Director, Research, Medical and Innovation, Association of the British Pharmaceutical Industry (ABPI), UK
19:00 – 20:00Poster Session
20.00 – lateWhiskey tasting and Special Performance
07:30 – 08:30Highlights of the Day and Press Briefing
07:00 – 08:00Meet the ProfessorMeet the Professor/Business LeaderMeet the Policy MakerMeet the Patient AdvocateMeet the Professor/Business Leader
08:00 – 09:30Presidential Session: Public-private partnership and personalised medicine
Chair: Pierre Meulien Innovation Medicines Initiative (IMI)
Kaja KALLAS, Member of the European Parliament (TBC)
Francesco De Lorenzo, President, European Cancer Patient Coalition, Brussels, Belgium
Speakers to be confirmed
09:30 – 10:00Coffee, Posters and Networking
10:00 – 11:30Parallel Sessions
 The Challenges of Precision Oncology Drug Development and ImplementationPersonalised Health and neglected diseaseWe are what we eat – preserving health through enhanced nutritionNo Pathology, No Personalised Medicine! 
Co Chair: Andrew Biankin, Regius Chair of Surgery/Director of Translational Research Centre, University of Glasgow,Chair: Alastair Kent, Chair Rare Disease UK; Director, Genetic Alliance UKChair: Christopher Elliott, Chair of Food Safety & Microbiology, Pro Vice Chancellor Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, UKCo-Chair: Kathy Oliver, Founding Co-Director, International Brain Tumour Alliance (IBTA) (TBC)
Co Chair: Simon Hollingsworth, Executive Director Oncology; Global Project Director, AstraZeneca, Cambridge, UKSpeaker to be confirmedCo-Chair Kenneth Fleming, Senior Adviser for Pathology, Centre for Global Health NCI, Washington
“Challenges of Contemporary Therapeutic Development” Simon Hollingsworth, Executive Director Oncology; Global Project Director, AstraZeneca, Cambridge, UKYann Le Cam, Chief Executive Officer of EURORDIS-Rare Diseases Europe (TBC)Precision Nutritional Catering for the Vulnerable: Can this be achieved?” Professor Moira Dean, Institute for Global Food Security, Queen’s University, Belfast –Kenneth Fleming, Senior Adviser for Pathology, Centre for Global Health NCI, Washington
“Diversity and Defining Actionability of Molecular Events” Philip Beer, Precision oncology, cancer genomics and next-generation therapeutics – ‎Cure Forward Corp., Cambridge, UKAnders Olauson, Chair, NGO Committee for Rare Diseases, United Nations, New York“Delivering a breakthrough in human nutrition and health through delivery of omega oils in chicken meat” Professor Alice Stanton, Royal College of Surgeons in Ireland, Dublin, IrelandJohn Flanigan, Senior Advisor for Non Communicable Diseases, Center for Global Health, National Cancer Institute, USA   (TBC)
“Finding patient for trials/Finding Trials for Patients” IBM Watson Speaker (TBC)Maria Luisa Silva, Director of United Nations Development Program (UNDP) Office in Geneva, Switzerland (TBC)Speaker to be confirmedManuel Salto Tellez, Chair of Molecular Pathology, Queen’s University Belfast, UK
“Effective Strategies for approval and adoption” Robert Hemmings, Krishna Prasad MHRA (TBC)Ana Rath, Director, Orphanet, Paris, FranceSue Horton, Professor and GICI Chair in Global Health Economics, University of Waterloo, Canada (TBC)
Composite Datasets and Knowledge Banks” Andrew Biankin, Regius Chair of Surgery/Director of Translational Research Centre, University of Glasgow, UKLai Meng Looi, Senior Professor of Pathology, University of Malaya, Malaysia (TBC)
11:30 – 12:00Proffered Paper Presentations?Proffered Paper Presentations?Proffered Paper Presentations?Proffered Paper Presentations?Proffered Paper Presentations?
12:00 – 13:00Lunch, Posters and Networking
13:00 – 14:30Presidential Session: Regulating the future – Balance of patient safety and facilitating Innovation (EMA – FDA)
Chair: Denis Horgan, Executive Director, European Alliance for Personalised Medicine
Emily O’ Reilly, European Ombudsman (TBC)
Robert Nussbaum Chief Medical Officer Invitae (TBC)
Urve Palo, Minister of Entrepreneurship and Information Technology, Estonia (TBC)
Kathy Oliver, International Brain Tumor Alliance IBTA
Michael Zaiac, Vice President , Medical  Affairs , Haem/Onc, Celgene, Basel, Switzerland (TBC)
Guido Rasi, Executive Director, EMA, London, UK (TBC)
14:30 – 15:00Coffee, Posters and Networking
Speed Networking
Meet the Cancer PatientMeet the Diabetes PatientsMeet the Patient (Brain Diseases)Meet the Patient with co-morbiditiesMeet the Rare Disease Patient
15:00 – 16:30Parallel Sessions
EAU Special Session Every Prostate cancer is unique: Personalised prostate cancer diagnosis and managementDiscovery Network: a new approach to driving researchDiabetes: A Personalised Health EpidemicMolecular Diagnostics – Enabling the Personalised Medicine RevolutionHTA, Payers & the European Medicines Agency – Crossing the Rubicon
Chair: Hain Van Poppel, European Association of UrologyChair: Peter Kaptein, Inspire2Live, The NetherlandsChair: Olivier Arnaud, Senior Director, Juvenile Diabetes Research FoundationCo-Chair: David Barton, National Centre for Medicial Genetics Crumlin;
Co-Chair: Mario Pazzagli, University of Florence, Italy
Chair: Lou Garrison, University of Washington, USA
Nicolas Mottet, Urology Department Head at CHU St Etienne – ‎Université Jean Monnet, St Etienne, FranceStephen Friend, Chairman, Co-Founder and Past President Sage Bionetworks; Leader Health Team, Apple Inc.Speakers to be confirmedThe new IVD regulation” – David Barton, Chief Scientist, National Centre for Medical Genetics Crumlin; (TBC)Clare Hague, Director of Health Economics & Outcomes research Medical Affairs, Celgene
Rodolfo Montironi, President, International Society of Urological Pathology, Ancona, ItalyMark Lawler, Chair in Translational Cancer Genomics, Queen’s University Belfast, UK“A Workflow for molecular diagnostics in clinical oncology” – Mario Pazzagli, Professor of Clinical Biochemistry, Department of Clinical and Experimental Biochemical Science University of Florence, Italy (TBC)Carole Longson, Director, Centre for Health Technology Evaluation and Executive Director, National Institute for Health Care & Excellence (NICE), London, UK
Speakers to be confirmedCharles Sawyers, Chair, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Centre, New York, USA (TBC)“Quality Assessment of Molecular Diagnostics in Oncology” Victoria Wurcel, Manager HTA and Economic Policies, MedTech Europe, Brussels, BelgiumHans-Georg Eichler, MD, MSc, Senior Medical Officer, European Medicines Agency (EMA), London, UK
Ian Banks, President, European Men’s Health ForumRobert Jan Smits, Director-General of DG Research and Innovation – European Commission (TBC)“Benchmarking the quality of next generation sequencing in Clinical Oncology” Simon Patton, Director at European Molecular Genetics Quality Network (EMQN) – ‎European Molecular Genetics Quality Network (EMQN) (TBC)Lars Pedersen, MSc, PhD, Professor, Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark (TBC)
Rob Vries, Hubrecht institute/ The HUB foundation for Organoid technology, Hubrecht, The Netherlands
Casper Van Eijck, Surgeon at Erasmus MC – Rotterdam, The Netherlands
16:30 – 17:30Closing of conference: Keeping the promise and preparing for the future
Jevgeni Ossinovski, Minister of Health, Estonia (TBC)
Vytenis Andriukaitis, European Commissioner for Health and Food Safety, Brussels, Belgium (TBC)
David Byrne, Chair European Alliance for Personalised Medicine, Brussels, Belgium
Charles Sawyers, Chair, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Centre, New York, USA (TBC)
Stephen Friend, Chairman, Co-Founder and Past President Sage Bionetworks; Leader Health Team, Apple Inc.